RHYTHM PHARMACEUTICALS, INC. Foreign Currency Transaction Gain (Loss), Unrealized
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$337.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was $1.01M, a 40.61% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$1.35M.
- RHYTHM PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was -$1.27M.
- RHYTHM PHARMACEUTICALS, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-06-30 was $1.71M.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month |
|---|---|---|---|
| 2026-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$337.00K 10-Q · filed 2026-08-04 | |
| 2026-03-31 | -$1.35M 10-Q · filed 2026-05-05 | ||
| 2025-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $439.00K derived: sum of 2 quarters · filed 2026-08-04 | $439.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.71M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |